The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women
- PMID: 11204125
- DOI: 10.1086/317936
The evolution of Candida species and fluconazole susceptibility among oral and vaginal isolates recovered from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women
Abstract
Antifungal agents can effectively treat mucosal candidiasis; however, their use can lead to colonization with less susceptible species and to resistance among normally susceptible strains. Oral and vaginal Candida isolates obtained at 3 points over 2 years from human immunodeficiency virus (HIV)-seropositive and at-risk HIV-seronegative women were identified by species and were evaluated for in vitro fluconazole susceptibility. Prevalence of non-C. albicans strains increased over time, and these strains were more likely among women reporting current antifungal use. Among C. albicans isolates, resistance was rare, with no evidence for progressive reduction in susceptibility over time. Among non-C. albicans isolates, reduced susceptibility occurred frequently and increased with time. HIV-seropositive women were more likely to have non-C. albicans isolates with reduced susceptibility as were women reporting current antifungal use. This evolution and section of mucosa-colonizing Candida species with reduced susceptibility could play a critical early role in the development of antifungal resistance among C. albicans isolates responsible for refractory candidiasis.
Similar articles
-
The Evolution of Candida Species and Fluconazole Susceptibility among Oral and Vaginal Isolates Recovered from Human Immunodeficiency Virus (HIV)-Seropositive and At-Risk HIV-Seronegative Women.J Infect Dis. 2000 Jan;183(2):286-293. J Infect Dis. 2000. PMID: 11110650
-
Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis.Clin Infect Dis. 2001 Oct 1;33(7):1069-75. doi: 10.1086/322641. Epub 2001 Sep 5. Clin Infect Dis. 2001. PMID: 11528582 Clinical Trial.
-
Isolation, characterization and antifungal susceptibility pattern of Candida species causing oropharyngeal candidiasis in HIV positive patients.J Commun Dis. 2008 Sep;40(3):177-81. J Commun Dis. 2008. PMID: 19245155
-
[Changes in epidemiology of opportunistic infections due to Candida].Rev Clin Esp. 1995 Oct;195 Suppl 3:1-3. Rev Clin Esp. 1995. PMID: 9441300 Review. Spanish. No abstract available.
-
Resistance to antifungal agents in the critical care setting: problems and perspectives.New Horiz. 1996 Aug;4(3):338-44. New Horiz. 1996. PMID: 8856751 Review.
Cited by
-
Antimicrobial Resistance in Vulvovaginitis.Curr Infect Dis Rep. 2001 Dec;3(6):546-549. doi: 10.1007/s11908-001-0093-5. Curr Infect Dis Rep. 2001. PMID: 11722813
-
Fluconazole Prophylaxis in Prevention of Symptomatic Candida Vaginitis.Curr Infect Dis Rep. 2020 Jan 21;22(1):2. doi: 10.1007/s11908-020-0712-7. Curr Infect Dis Rep. 2020. PMID: 31965356 Review.
-
Invasive oesophageal candidiasis: current and developing treatment options.Drugs. 2003;63(10):971-89. doi: 10.2165/00003495-200363100-00004. Drugs. 2003. PMID: 12699400 Review.
-
Microdilution in vitro Antifungal Susceptibility Patterns of Candida Species, From Mild Cutaneous to Bloodstream Infections.Jundishapur J Microbiol. 2016 Jul 5;9(7):e34151. doi: 10.5812/jjm.34151. eCollection 2016 Jul. Jundishapur J Microbiol. 2016. PMID: 27679703 Free PMC article.
-
Determinants of symptomatic vulvovaginal candidiasis among human immunodeficiency virus type 1 infected women in rural KwaZulu-Natal, South Africa.Infect Dis Obstet Gynecol. 2014;2014:387070. doi: 10.1155/2014/387070. Epub 2014 Apr 9. Infect Dis Obstet Gynecol. 2014. PMID: 24812479 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical